Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol- bisbenzonitrile in vitro

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 5, 2009, Pages 867-875

  Jeong, Seongwook ^a,b   Woo, Margaret M ^c   Flockhart, David A ^a   Desta, Zeruesenay ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chonnam National University Medical School   (South Korea)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aromatase inhibitor; Cytochrome P450; Drug interaction; Letrozole; Metabolite

Indexed keywords

4,4' METHANOL BISBENZONITRILE; BENZONITRILE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG METABOLITE; LETROZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; AROMATASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MICROSOMES, LIVER; NADP; NITRILES; TRIAZOLES;

EID: 69049103060     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0935-7     Document Type: Article

References (37)

1. JD Yager NE Davidson 2006 Estrogen carcinogenesis in breast cancer N Engl J Med 354 270 282
2. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med 339 1609 1618
3. AU Buzdar JF Robertson 2006 Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer Ann Pharmacother 40 1572 1583
4. IE Smith M Dowsett 2003 Aromatase inhibitors in breast cancer N Engl J Med 348 2431 2442
5. KJ Ryan 1959 Biological aromatization of steroids J Biol Chem 234 268 272
6. LJ Scott SJ Keam 2006 Letrozole: in postmenopausal hormone-responsive early-stage breast cancer Drugs 66 353 362
7. B Thurlimann A Keshaviah AS Coates et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757
8. RC Coombes E Hall LJ Gibson et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
9. AU Buzdar RC Coombes PE Goss EP Winer 2008 Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer Cancer 112 700 709
10. Y Jin Z Desta V Stearns et al. 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39
11. S Borges Z Desta L Li et al. 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74
12. AS Bhatnagar 2007 The discovery and mechanism of action of letrozole Breast Cancer Res Treat 105 Suppl 1 7 17
13. B Wrz B Valles A Parkinson A Madan A Probst A Zimmerlin J Gut 1996 CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole ISSX Proc 10 359 (Abstract)
14. SW Grimm MC Dyroff 1997 Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase Drug Metab Dispos 25 598 602
15. K Venkatakrishnan LL Von Moltke DJ Greenblatt 2000 Effects of the antifungal agents on oxidative drug metabolism: clinical relevance Clin Pharmacokinet 38 111 180
16. Z Desta BA Ward DA Flockhart 2005 In vitro letrozole N-dealkylation is mainly catalyzed by human cytochrome P450 (CYP) 3A Clin Pharmacol Ther 77 79 (Abstract)
17. Product information. Novartis Pharmaceutical Canada Inc. Prescribing information femara1 (letrozole). http://www.pharma.ca.novartis.com/downloads/e/ femara-scrip-e.pdf (online 23 April 2007)
18. CU Pfister A Martoni C Zamagni et al. 2001 Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients Biopharm Drug Dispos 22 191 197
19. X Tao H Piao DJ Canney MR Borenstein IP Nnane 2007 Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen J Pharm Biomed Anal 43 1078 1085
20. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal Biochem 72 248 254
21. S Jeong PD Nguyen Z Desta 2009 Comprehensive in vitro inhibition analysis of 8 cytochrome P450 (CYP) enzymes by voriconazole: major effect on CYPs 2B6, 2C9, 2C19 and 3A Antimicrob Agents Chemother 53 541 551
22. JW Ko N Sukhova D Thacker P Chen DA Flockhart 1997 Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms Drug Metab Dispos 25 853 862
23. WF Greenlee A Poland 1978 An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin J Pharmacol Exp Ther 205 596 605
24. R Pearce D Greenway A Parkinson 1992 Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation Arch Biochem Biophys 298 211 225
25. AJ Draper A Madan A Parkinson 1997 Inhibition of coumarin 7-hydroxylase activity in human liver microsomes Arch Biochem Biophys 341 47 61
26. BA Ward JC Gorski DR Jones SD Hall DA Flockhart Z Desta 2003 The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity J Pharmacol Exp Ther 306 287 300
27. XQ Li A Bjorkman TB Andersson M Ridderstrom CM Masimirembwa 2002 Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate J Pharmacol Exp Ther 300 399 407
28. S Parikh JB Ouedraogo JA Goldstein PJ Rosenthal DL Kroetz 2007 Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa Clin Pharmacol Ther 82 197 203
29. YH Wang DR Jones SD Hall 2005 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil Drug Metab Dispos 33 664 671
30. Z Desta T Kerbusch N Soukhova E Richard JW Ko DA Flockhart 1998 Identification and characterization of human cytochrome P450 isoforms interacting with pimozide J Pharmacol Exp Ther 285 428 437
31. Z Desta N Soukhova SK Mahal DA Flockhart 2000 Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies Drug Metab Dispos 28 789 800
32. M Bourrie V Meunier Y Berger G Fabre 1996 Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes J Pharmacol Exp Ther 277 321 332
33. DM Colussi CY Parisot GY Lefevre 1998 Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor J Clin Pharmacol 38 727 735
34. C Xu S Goodz EM Sellers RF Tyndale 2002 CYP2A6 genetic variation and potential consequences Adv Drug Deliv Rev 54 1245 1256
35. A Sioufi N Gauducheau V Pineau et al. 1997 Absolute bioavailability of letrozole in healthy postmenopausal women Biopharm Drug Dispos 18 779 789
36. XD Liu L Xie Y Zhong CX Li 2000 Gender difference in letrozole pharmacokinetics in rats Acta Pharmacol Sin 21 680 684
37. JN Ingle VJ Suman PA Johnson et al. 1999 Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer Clin Cancer Res 5 1642 1649